SCHEMBL4924893

SCHEMBL4924893

O=C(Nc1c(F)cccc1F)c1ccc(Cc2cc(Cl)ccc2OCc2ccc(Cl)cc2F)o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
ALDH1A1 P00352 1/20 0.55
PTGER1 P34995 6/20 0.54
CYP1A2 P05177 3/20 0.53
CYP2C9 P11712 3/20 0.53
CYP2C19 P33261 3/20 0.53
TBXA2R P21731 2/20 0.53
PTGS1 P23219 2/20 0.53
PTGER3 P43115 2/20 0.53
PTGER2 P43116 2/20 0.53
NPSR1 Q6W5P4 2/20 0.50
LMNA P02545 1/20 0.50
S1PR4 O95977 1/20 0.49
CYP3A4 P08684 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919335 0.95 PTGER1 (0.55) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4914154 0.94 GAA (0.58) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4926308 0.94 GAA (0.59) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4924878 0.94 SMN1; SMN2 (0.55) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4923036 0.92 PTGER1 (0.61) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4917875 0.92 SMN1; SMN2 (0.55) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4925046 0.91 SMN1; SMN2 (0.56) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4927580 0.91 PTGER1 (0.56) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4926019 0.91 PTGER1 (0.67) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2
SCHEMBL4925217 0.91 PTGER1 (0.59) GAASMN1; SMN2ALDH1A1PTGER1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287430-A1 Furan Compounds Useful As Ep1 Receptor Antagonists PTGER1, PTGER2, PTGER3 GAA 4729/4885SMN1; SMN2 3450/4885ALDH1A1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.